Research programme - IL-17 antagonist - DICE Therapeutics
Alternative Names: IL-17 antagonist-DICE-Therapeutics; Novel scaffold program #1 (Fast follower); Novel scaffold program #2Latest Information Update: 11 Aug 2023
At a glance
- Originator DiCE Molecules
- Developer DICE Therapeutics
- Class Antipsoriatics; Small molecules
- Mechanism of Action Interleukin 17 receptor antagonists; Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders; Psoriasis